vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Legacy Education Inc. (LGCY). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $19.2M, roughly 1.9× Legacy Education Inc.). Legacy Education Inc. runs the higher net margin — 10.6% vs -3.7%, a 14.3% gap on every dollar of revenue. On growth, Legacy Education Inc. posted the faster year-over-year revenue change (40.7% vs 33.4%). Legacy Education Inc. produced more free cash flow last quarter ($512.7K vs $-5.8M).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

Legacy Education Inc. is a professional educational service provider focused on financial literacy, real estate investment, entrepreneurship, and personal wealth management training programs. It mainly serves individual learners across North America, Europe and select Asia-Pacific markets, offering both in-person workshops and online digital courses to help users build practical financial and business skills.

GYRE vs LGCY — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.9× larger
GYRE
$37.2M
$19.2M
LGCY
Growing faster (revenue YoY)
LGCY
LGCY
+7.3% gap
LGCY
40.7%
33.4%
GYRE
Higher net margin
LGCY
LGCY
14.3% more per $
LGCY
10.6%
-3.7%
GYRE
More free cash flow
LGCY
LGCY
$6.3M more FCF
LGCY
$512.7K
$-5.8M
GYRE

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
GYRE
GYRE
LGCY
LGCY
Revenue
$37.2M
$19.2M
Net Profit
$-1.4M
$2.0M
Gross Margin
95.3%
Operating Margin
0.3%
13.3%
Net Margin
-3.7%
10.6%
Revenue YoY
33.4%
40.7%
Net Profit YoY
-340.1%
46.0%
EPS (diluted)
$-0.01
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
LGCY
LGCY
Q4 25
$37.2M
$19.2M
Q3 25
$30.6M
$19.4M
Q2 25
$26.8M
$18.0M
Q1 25
$22.1M
$18.6M
Q4 24
$27.9M
$13.6M
Q3 24
$25.5M
$14.0M
Q2 24
$25.2M
Q1 24
$27.2M
Net Profit
GYRE
GYRE
LGCY
LGCY
Q4 25
$-1.4M
$2.0M
Q3 25
$5.9M
$2.2M
Q2 25
$1.6M
$1.2M
Q1 25
$3.7M
$2.8M
Q4 24
$569.0K
$1.4M
Q3 24
$2.9M
$2.1M
Q2 24
$4.5M
Q1 24
$9.9M
Gross Margin
GYRE
GYRE
LGCY
LGCY
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
Q2 24
96.9%
Q1 24
96.4%
Operating Margin
GYRE
GYRE
LGCY
LGCY
Q4 25
0.3%
13.3%
Q3 25
22.7%
13.9%
Q2 25
8.1%
11.1%
Q1 25
10.3%
19.7%
Q4 24
2.4%
12.2%
Q3 24
16.6%
19.1%
Q2 24
12.7%
Q1 24
29.7%
Net Margin
GYRE
GYRE
LGCY
LGCY
Q4 25
-3.7%
10.6%
Q3 25
19.4%
11.3%
Q2 25
5.9%
6.8%
Q1 25
16.9%
15.2%
Q4 24
2.0%
10.3%
Q3 24
11.2%
14.9%
Q2 24
18.0%
Q1 24
36.6%
EPS (diluted)
GYRE
GYRE
LGCY
LGCY
Q4 25
$-0.01
$0.15
Q3 25
$0.03
$0.16
Q2 25
$0.00
$0.07
Q1 25
$0.00
$0.21
Q4 24
$0.00
$0.10
Q3 24
$0.01
$0.21
Q2 24
$0.01
Q1 24
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
LGCY
LGCY
Cash + ST InvestmentsLiquidity on hand
$52.4M
$21.1M
Total DebtLower is stronger
$660.3K
Stockholders' EquityBook value
$106.0M
$46.1M
Total Assets
$166.1M
$73.1M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
LGCY
LGCY
Q4 25
$52.4M
$21.1M
Q3 25
$60.0M
$20.6M
Q2 25
$54.4M
$20.3M
Q1 25
$29.9M
$17.3M
Q4 24
$26.7M
$16.9M
Q3 24
$25.1M
$21.5M
Q2 24
$25.1M
Q1 24
$37.4M
Total Debt
GYRE
GYRE
LGCY
LGCY
Q4 25
$660.3K
Q3 25
$776.9K
Q2 25
$1.4M
Q1 25
$1.0M
Q4 24
$1.1M
Q3 24
$758.2K
Q2 24
Q1 24
Stockholders' Equity
GYRE
GYRE
LGCY
LGCY
Q4 25
$106.0M
$46.1M
Q3 25
$101.9M
$43.7M
Q2 25
$92.0M
$41.0M
Q1 25
$68.1M
$39.3M
Q4 24
$63.3M
$36.4M
Q3 24
$63.2M
$32.6M
Q2 24
$60.4M
Q1 24
$56.6M
Total Assets
GYRE
GYRE
LGCY
LGCY
Q4 25
$166.1M
$73.1M
Q3 25
$159.4M
$72.1M
Q2 25
$152.6M
$69.2M
Q1 25
$129.8M
$67.1M
Q4 24
$125.4M
$62.1M
Q3 24
$125.2M
$50.6M
Q2 24
$120.9M
Q1 24
$122.0M
Debt / Equity
GYRE
GYRE
LGCY
LGCY
Q4 25
0.01×
Q3 25
0.02×
Q2 25
0.03×
Q1 25
0.03×
Q4 24
0.03×
Q3 24
0.02×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
LGCY
LGCY
Operating Cash FlowLast quarter
$-5.6M
$1.1M
Free Cash FlowOCF − Capex
$-5.8M
$512.7K
FCF MarginFCF / Revenue
-15.5%
2.7%
Capex IntensityCapex / Revenue
0.4%
2.8%
Cash ConversionOCF / Net Profit
0.52×
TTM Free Cash FlowTrailing 4 quarters
$-180.0K
$4.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
LGCY
LGCY
Q4 25
$-5.6M
$1.1M
Q3 25
$4.7M
$1.1M
Q2 25
$2.1M
$3.0M
Q1 25
$-129.0K
$918.7K
Q4 24
$-2.8M
$659.0K
Q3 24
$1.7M
$3.2M
Q2 24
$-5.5M
Q1 24
$2.9M
Free Cash Flow
GYRE
GYRE
LGCY
LGCY
Q4 25
$-5.8M
$512.7K
Q3 25
$4.0M
$809.7K
Q2 25
$1.8M
$2.9M
Q1 25
$-251.0K
$596.6K
Q4 24
$-2.8M
$466.8K
Q3 24
$1.0M
$2.9M
Q2 24
$-6.9M
Q1 24
$2.7M
FCF Margin
GYRE
GYRE
LGCY
LGCY
Q4 25
-15.5%
2.7%
Q3 25
13.1%
4.2%
Q2 25
6.8%
16.2%
Q1 25
-1.1%
3.2%
Q4 24
-10.1%
3.4%
Q3 24
4.1%
21.1%
Q2 24
-27.5%
Q1 24
9.8%
Capex Intensity
GYRE
GYRE
LGCY
LGCY
Q4 25
0.4%
2.8%
Q3 25
2.2%
1.3%
Q2 25
1.0%
0.5%
Q1 25
0.6%
1.7%
Q4 24
0.2%
1.4%
Q3 24
2.7%
1.7%
Q2 24
5.8%
Q1 24
0.9%
Cash Conversion
GYRE
GYRE
LGCY
LGCY
Q4 25
0.52×
Q3 25
0.79×
0.48×
Q2 25
1.32×
2.45×
Q1 25
-0.03×
0.33×
Q4 24
-4.85×
0.47×
Q3 24
0.60×
1.52×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons